New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress in Madrid. The company says the research highlighted at this year's meeting reinforces Lilly's commitment to developing treatments for individuals living with dermatological conditions such as psoriasis, psoriatic arthritis, atopic dermatitis and alopecia areata.  

Lilly presented findings from a Phase 3 trial of Taltz for pediatric patients with moderate to severe psoriasis as a late-breaking oral presentation at this year's EADV meeting. The company also shared results from a patient survey evaluating treatment expectations and burden of disease for patients living with psoriasis. 

For baricitinib, Lilly presented a late-breaking presentation of the BREEZE-AD7 clinical trial. BREEZE-AD7 is an investigational study measuring the efficacy and safety of baricitinib in combination with topical corticosteroids for the treatment of moderate to severe atopic dermatitis (AD) in adults. Lilly and Incyte Corporation (NASDAQ: INCY) are partners in the clinical development of baricitinib. Further, Lilly will present data findings from a real-world study assessing how elements of an individual's quality of life (both functional and emotional) may be impacted by AD.

Posters around Lilly's investigational compound, mirikizumab, include research measuring patient outcomes and health-related elements of quality of life for individuals with moderate to severe psoriasis.

At the 5thAnnual Maui Derm NP+PA Fall meeting, results of the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint, show Taltz met the primary endpoint of superiority vs. guselkumabin the proportion of patients with moderate to severe plaque psoriasis achieving complete skin clearance as measured by PASI 100 at Week 12, as well as key secondary endpoints. The study is ongoing through Week 24.Additionally, all major secondary endpoints up to Week 12 were achieved (P<0.001).